A Multi-center, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of CSJ148 Compared to Placebo to Prevent Human Cytomegalovirus (HCMV) Replication in Stem Cell Transplant Patients
Phase of Trial: Phase I/II
Latest Information Update: 22 Mar 2017
At a glance
- Drugs CSJ 148 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 17 Jan 2017 Status changed from recruiting to completed.
- 06 Jul 2016 Planned End Date changed from 1 Apr 2017 to 1 Jan 2017.
- 06 Jul 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Jan 2017.